Heart failure therapy sacubitril/valsartan (Novartis AG’s Entresto) and cut-price versions of itraconazole (Johnson & Johnson’s Sporanox) and azilsartan (Takeda Pharmaceutical Co. Ltd.’s Edarbi) are among recent new introductions that have made an impressive start on the Indian market.
Entresto, which has seen galloping growth internationally, appears to have given Novartis a lot to cheer about in India. In...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

